A nasal CGRP receptor antagonist for acute migraine therapy.

Competing Interests: I have received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, and educational events from AbbVie, Allergan, Amgen, Lilly, Lundbeck, Medscape, streamedup!, Novartis, Pfizer, and Teva Pharmaceuticals; and consulting fees from AbbVie, Allergan, Amgen, Lilly, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals. I have received research support from the German Federal Ministry of Education and Research (Innovationsfond 01NVF17038) and Novartis. I serve as Treasurer of the European Headache Federation, and I am Associate Editor of The Journal of Headache and Pain and Frontiers in Neurology.